Provepharm, Martindale to supply Proveblue for injection in UK, Ireland
As per the terms of the partnership, Martindale Pharma will take charge of commercial activities relating to Proveblue in the UK and Ireland. The commercial terms of the
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The study published as a research article, ‘Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes’ investigated the details of a novel proteomics based method in detecting inhibition